This year we had the honour of being invited to present in collaboration with Agilent Technologies on SelectScience multiple times. First, we presented our human in vitro T cell exhaustion model and quite recently we had our second webinar together where we discussed our transformational in vitro cell-based platform, IndEx-2.

In this webinar, one of the inventors of IndEx-2, Dr. Timothy London, Scientific Director of Molecular Biology at Antibody Analytics presents IndEx-2, our transformational in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels. 

By integrating IndEx-2 with tools such as the Agilent xCELLigence Real Time Cell Analyzer (RTCA), NovoCyte Flow Cytometer, and cytokine release measurement protocols, the antigen density thresholds required for the activation of potential immunotherapeutic candidates can be determined.

Importantly, this comprehensive approach caters to a diverse array of functional readouts, spanning from cytotoxic responses to immune cell activation. This way IndEx-2 can be easily integrated with immune-oncology primary cell assays, to provide a complete picture of a targeted drug candidate’s mechanism of action and safety profile.

Let’s look further into this powerful cell line system as presented by our Scientific Director of Molecular Biology, Dr. Timothy London: watch our video.

Understand target antigen density in cancer treatments

If you have any questions about how to apply IndEx-2 to the pre-clinical discovery of any antibody-targeted therapy like CAR-engineered cell therapies, bispecific antibodies, multispecifics, immune cell engagers, monoclonal antibodies or ADCs, simply get in touch with our scientific team; they are happy to assist you. Book a meeting with them here: 

Stay tuned to our blog for the most up-to-date news and a wealth of additional scientific resources.